BioNTech Results Presentation Deck

Key Highlights For 2021 Financial Year €18.8 bn €14.8 bn €3.0 bn €1.0 bn FY 2021 26 COVID-19 Vaccine Commercial Revenues¹: €18.8 bn Share of gross profit and sales milestones from COVID-19 vaccine sales in the Pfizer and Fosun Pharma territory (100% gross margin) Direct COVID-19 vaccine sales to customers in BioNTech's territory ■COVID-19 Sales to collaboration partners of products manufactured by BioNTech Doses: ~2.6 bn delivered Revenues and margins exceeded expectations 1 BioNTech's profit share is estimated based on preliminary data shared between Pfizer and BioNTech as further described in the Annual Report on Form 20-F for the year ended December 31, 2021. Any changes in the estimated share of the collaboration partner's gross profit will be recognized prospectively. Low- and Middle-Income Countries 40% High-Income Countries 60% BIONTECH

View entire presentation